Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Human Clinical Trial Shows Stem Cell Therapy Hastens Bone Repair

By BiotechDaily International staff writers
Posted on 11 Jul 2013
Treatment of fractures of the pelvic bones with stem cells halved recovery time in a clinical study conducted over the past four years.

Investigators at the Hadassah Medical Organization (Jerusalem, Israel) worked with a group of 24 patients with severe pelvis fractures. Breaks of this kind are especially slow to heal due to the scant layer of muscle and bone support tissue present as well as reduced blood supply.

The protocol used in this study called for 50 milliliters of bone marrow and 100 milliliters of blood to be extracted from the patient's pelvic area. Mesenchymal stem cells were isolated from the bone marrow, and an enriched platelet fraction was prepared from the blood. The stem cells and enriched platelet fraction were mixed with demineralized bone matrix (DBM) and injected under fluoroscopic control into the fracture site. A control group did not receive stem cells.

Results published in the June 4, 2013, online edition of the journal Molecular Therapy revealed that the stem cell therapy was a safe and efficient procedure, as no complications occurred in either group. The median time for bone repair was 1.5 months in the stem cell treated group and three months in the control group.

First author Dr. Meir Liebergall, professor of orthopedic surgery at the Hadassah Medical Organization, said, “A process that began 15 years ago eventually led to this clinical trial at Hadassah, the first of its kind in Israel. The trial included 24 patients with severe pelvis fractures. This research is a medical breakthrough. Publication of this study and its findings will most likely change the currently accepted principles of treating complicated fractures. Now, we face the challenge of understanding this healing mechanism and how it works.”

Related Links:

Hadassah Medical Organization




Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.